scholarly journals Porcine Bladder Urothelial, Myofibroblast, and Detrusor Muscle Cells: Characterization and ATP Release

2011 ◽  
Vol 2 ◽  
Author(s):  
Ying Cheng ◽  
Kylie J. Mansfield ◽  
Shaun L. Sandow ◽  
Prajni Sadananda ◽  
Elizabeth Burcher ◽  
...  
2020 ◽  
Vol 21 (22) ◽  
pp. 8608
Author(s):  
Victoria Moreno-Manzano ◽  
Daria Zaytseva-Zotova ◽  
Eric López-Mocholí ◽  
Álvaro Briz-Redón ◽  
Berit Løkensgard Strand ◽  
...  

Biologic scaffolds composed of extracellular matrix components have been proposed to repair and reconstruct a variety of tissues in clinical and pre-clinical studies. Injectable gels can fill and conform any three-dimensional shape and can be delivered to sites of interest by minimally invasive techniques. In this study, a biological gel was produced from a decellularized porcine urinary bladder by enzymatic digestion with pepsin. The enzymatic digestion was confirmed by visual inspection after dissolution in phosphate-buffered saline solution and Fourier-transform infrared spectroscopy. The rheological and biological properties of the gel were characterized and compared to those of the MatrigelTM chosen as a reference material. The storage modulus G’ reached 19.4 ± 3.7 Pa for the 30 mg/mL digested decellularized bladder gels after ca. 3 h at 37 °C. The results show that the gel formed of the porcine urinary bladder favored the spontaneous differentiation of human and rabbit adipose-derived stem cells in vitro into smooth muscle cells to the detriment of cell proliferation. The results support the potential of the developed injectable gel for tissue engineering applications to reconstruct for instance the detrusor muscle part of the human urinary bladder.


BMC Urology ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
José Pontes-Júnior ◽  
Ricardo Luís Vita Nunes ◽  
Sabrina Thalita dos Reis ◽  
Luiz Carlos N de Oliveira ◽  
Nayara Viana ◽  
...  

2019 ◽  
Vol 176 (24) ◽  
pp. 4720-4730 ◽  
Author(s):  
Carly J. McCarthy ◽  
Youko Ikeda ◽  
Deborah Skennerton ◽  
Basu Chakrabarty ◽  
Anthony J. Kanai ◽  
...  

2009 ◽  
Vol 296 (4) ◽  
pp. C828-C839 ◽  
Author(s):  
Domenick A. Prosdocimo ◽  
Dezmond C. Douglas ◽  
Andrea M. Romani ◽  
W. Charles O'Neill ◽  
George R. Dubyak

Extracellular inorganic pyrophosphate (PPi) is a potent suppressor of physiological calcification in bone and pathological calcification in blood vessels. Ectonucleotide pyrophosphatase/phosphodiesterases (eNPPs) generate PPi via the hydrolysis of ATP released into extracellular compartments by poorly understood mechanisms. Here we report that cultured vascular smooth muscle cells (VSMC) from rat aorta generate extracellular PPi via an autocrine mechanism that involves ATP release tightly coupled to eNPP activity. The nucleotide analog β,γ-methylene ATP (MeATP or AMPPCP) was used to selectively suppress ATP metabolism by eNPPs but not the CD39-type ecto-ATPases. In the absence of MeATP, VSMC generated extracellular PPi to accumulate ≥600 nM within 2 h while steadily maintaining extracellular ATP at 1 nM. Conversely, the presence of MeATP completely suppressed PPi accumulation while increasing ATP accumulation. Probenecid, which inhibits PPi efflux dependent on ANK, a putative PPi transporter or transport regulator, reduced extracellular PPi accumulation by approximately twofold. This indicates that autocrine ATP release coupled to eNPP activity comprises ≥50% of the extracellular PPi-generating capacity of VSMC. The accumulation of extracellular PPi and ATP was markedly attenuated by reduced temperature but was insensitive to brefeldin A, which suppresses constitutive exocytosis of Golgi-derived secretory vesicles. The magnitude of extracellular PPi accumulation in VSMC cultures increased with time postplating, suggesting that ATP release coupled to PPi generation is upregulated as cultured VSMC undergo contact-inhibition of proliferation or deposit extracellular matrix.


Toxins ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 129 ◽  
Author(s):  
Yu-Hua Lin ◽  
Bing-Juin Chiang ◽  
Chun-Hou Liao

Intravesical botulinum toxin (BoNT) injection is effective in reducing urgency and urinary incontinence. It temporarily inhibits the detrusor muscle contraction by blocking the release of acetylcholine (Ach) from the preganglionic and postganglionic nerves in the efferent nerves. BoNT-A also blocks ATP release from purinergic efferent nerves in the detrusor muscle. In afferent nerves, BoNT-A injection markedly reduces the urothelial ATP release and increases nitric oxide (NO) release from the urothelium. BoNT-A injection in the urethra or bladder has been developed in the past few decades as the treatment method for detrusor sphincter dyssyndergia, incontinence due to neurogenic or idiopathic detrusor overactivity, sensory disorders, including bladder hypersensitivity, overactive bladder, and interstitial cystitis/chronic pelvic pain syndrome. Although the FDA only approved BoNT-A injection treatment for neurogenic detrusor overactivity and for refractory overactive bladder, emerging clinical trials have demonstrated the benefits of BoNT-A treatment in functional urological disorders. Cautious selection of patients and urodynamic evaluation for confirmation of diagnosis are crucial to maximize the successful outcomes of BoNT-A treatment.


2002 ◽  
Vol 137 (7) ◽  
pp. 1001-1010 ◽  
Author(s):  
J Y An ◽  
H S Yun ◽  
Y P Lee ◽  
S J Yang ◽  
J O Shim ◽  
...  

2013 ◽  
Vol 14 (5) ◽  
pp. 543-556
Author(s):  
Mingqing Wang ◽  
Ning Zhang ◽  
Wei Wang ◽  
Biao Wang ◽  
Zhiqing Xu ◽  
...  

2007 ◽  
Vol 105 (1) ◽  
pp. 57-65 ◽  
Author(s):  
Yumei Zhao ◽  
Keisuke Migita ◽  
Chiemi Sato ◽  
Sadaharu Usune ◽  
Takahiro Iwamoto ◽  
...  

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Jose Pontes-Junior ◽  
Ricardo L.V. Nunes ◽  
Sabrina T. dos Reis ◽  
Luciana S. Timosczuk ◽  
Katia R.M. Leite ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document